RLMD 最新10-Q变化
将 RLMD 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-06 与上一份 10-Q · 2026-05-12
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +37 | −18 | ~23 | 40 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 0 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | +3 | −1 | 0 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-06
● NDV-01 United States IND filing with the FDA by year-end 2026
● Sepranolone – United States IND filing with the FDA by year-end 2026
● Sepranolone - Initiation of a Phase 2 clinical trial in PWS – Upon IND clearance
Relmada expects to file a United States IND application for NDV-01 with the FDA by year-end 2026.
Relmada expects to file a United States IND application for sepranolone with the FDA by year-end 2026.
相对上期删除的文字 · 来源:10-Q · 2026-05-12
● NDV-01 United States Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA) to initiate a clinical trial in NMIBC – Mid-2026
● Sepranolone - Initiation of a Phase 2 clinical trial in PWS – Mid-2026
● NDV-01 Initial 3-Month Data from Phase 3 High-risk, 2nd line BCG-unresponsive NMIBC Trial – Year-end 2026
Relmada expects to initiate a Phase 2 pilot study of sepranolone in PWS in mid-2026.
For the Three Months Ended March 31, 2026 versus March 31, 2025
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-08-06
On May 18, 2026, Charles Ence, the Company’s Chief Accounting and Compliance Officer, adopted an individual trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act, which has a term of eight months beginning September 17, 2026 to sell up to 268,361 s…
On May 19, 2026, Charles Casamento, the Company’s Chairman of the Board of Directors, adopted an individual trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act, which has a term of twelve months beginning September 1, 2026 to sell up to 134,579 s…
No other directors or executive officers of the Company adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Report.
相对上期删除的文字 · 来源:10-Q · 2026-05-12
No directors or executive officers of the Company adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Report.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议